MCID: INC003
MIFTS: 35

Inclusion Conjunctivitis

Categories: Eye diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Inclusion Conjunctivitis

MalaCards integrated aliases for Inclusion Conjunctivitis:

Name: Inclusion Conjunctivitis 12 74 20 15 17 71
Chlamydial Conjunctivitis 12 32
Inclusion Conjunctivitis of the Adult 71
Neonatal Chlamydial Conjunctivitis 71
Adult Inclusion Conjunctivitis 12
Conjunctivitis, Inclusion 44
Inclusion Blennorrhoea 12
Inclusion Blenorrhea 12
Paratrachoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13800
ICD9CM 34 077.0
MeSH 44 D003235
SNOMED-CT 67 111840005
ICD10 32 A74.0
UMLS 71 C0009770 C0343723 C0392644

Summaries for Inclusion Conjunctivitis

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation, located in conjunctiva of the eye, has material basis in Chlamydia trachomatis, which is transmitted by sexual contact. The infection has symptom swollen conjunctiva and eyelids and has symptom discharge of pus and mucus.

MalaCards based summary : Inclusion Conjunctivitis, also known as chlamydial conjunctivitis, is related to chlamydia and conjunctival folliculosis, and has symptoms including swollen conjunctiva and discharge of pus. An important gene associated with Inclusion Conjunctivitis is CHORDC1 (Cysteine And Histidine Rich Domain Containing 1). The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include conjunctiva of the eye, eye and t cells.

Wikipedia : 74 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Inclusion Conjunctivitis

Diseases related to Inclusion Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 chlamydia 30.8 HTRA1 HSPD1
2 conjunctival folliculosis 30.3 HSPD1 CPN1
3 lymphogranuloma venereum 30.1 SPAG8 FBXO39 CPN1
4 chlamydia pneumonia 29.9 HSPD1 CPN1
5 ophthalmia neonatorum 29.9 SPAG8 HTRA1 FBXO39
6 cat-scratch disease 29.8 HTRA1 HSPD1
7 conjunctivitis 10.9
8 trachoma 10.7
9 chronic conjunctivitis 10.2
10 keratitis, hereditary 10.1
11 ornithosis 10.0
12 urethritis 10.0
13 bacillary angiomatosis 10.0 HTRA1 HSPD1
14 endemic typhus 10.0 HTRA1 HSPD1
15 bartonellosis 10.0 HTRA1 HSPD1
16 rocky mountain spotted fever 10.0 HTRA1 HSPD1
17 hand skill, relative 10.0
18 ptosis 10.0
19 bacterial infectious disease 10.0
20 acute hemorrhagic conjunctivitis 10.0
21 pyloric stenosis 10.0
22 uveitis 10.0
23 chronic follicular conjunctivitis 10.0
24 cellulitis 10.0
25 gastritis 10.0
26 adult acute lymphocytic leukemia 10.0
27 reactive arthritis 10.0
28 gastrointestinal system disease 10.0
29 arthritis 10.0
30 herpes simplex 10.0
31 chickenpox 10.0
32 cytokine deficiency 10.0
33 campylobacteriosis 10.0 HTRA1 HSPD1
34 granuloma inguinale 9.9 SPAG8 FBXO39 CPN1
35 lymphoma, mucosa-associated lymphoid type 9.9
36 otitis media 9.9
37 yemenite deaf-blind hypopigmentation syndrome 9.9
38 acute salpingitis 9.9
39 acute conjunctivitis 9.9
40 allergic disease 9.9
41 keratopathy 9.9
42 orchitis 9.9
43 cervicitis 9.9
44 eye disease 9.9
45 pyosalpinx 9.9
46 salpingitis 9.9
47 encephalitis 9.9
48 bacterial conjunctivitis 9.9
49 epidemic typhus 9.9 HTRA1 HSPD1
50 endocarditis 9.8 HTRA1 HSPD1

Graphical network of the top 20 diseases related to Inclusion Conjunctivitis:



Diseases related to Inclusion Conjunctivitis

Symptoms & Phenotypes for Inclusion Conjunctivitis

Symptoms:

12
  • swollen conjunctiva
  • discharge of pus

Drugs & Therapeutics for Inclusion Conjunctivitis

Drugs for Inclusion Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Povidone-iodine Approved Phase 3 25655-41-8
4
Iodine Approved, Investigational Phase 3 7553-56-2 807
5
Povidone Approved Phase 3 9003-39-8 131751496
6
Cadexomer iodine Experimental Phase 3 94820-09-4
7 Ophthalmic Solutions Phase 3
8 Pharmaceutical Solutions Phase 3
9 Antiviral Agents Phase 2
10 Anti-Inflammatory Agents Phase 2
11 Hormones Phase 2
12 Gastrointestinal Agents Phase 2
13 Hormone Antagonists Phase 2
14 Antineoplastic Agents, Hormonal Phase 2
15 glucocorticoids Phase 2
16 Antiemetics Phase 2
17
Azithromycin Approved 83905-01-5 55185 447043
18 Anti-Infective Agents
19 Anti-Bacterial Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis Terminated NCT02998541 Phase 3 SHP640;PVP-I 0.6%
2 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis Terminated NCT02998554 Phase 3 SHP640;Placebo
3 A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis Completed NCT01470664 Phase 2 FST-100;FST-100 (Component #1);FST-100 Vehicle
4 A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis Completed NCT01532336 Phase 2 NVC-422 Solution, 0.3%;NVC-422 Vehicle Solution
5 A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis Recruiting NCT03856645 Phase 2 OKG-0301
6 A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis Recruiting NCT03749317 Phase 2 IVIEW-1201;Placebo
7 FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis Terminated NCT00941486 Phase 2 FST-100 (0.1% dexamethasone) Ophthalmic Suspension;Placebo
8 An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis Terminated NCT00901693 Phase 2 AL-46383A Ophthalmic Solution;AL-46383A Ophthalmic Solution Vehicle
9 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Azithromycin
10 A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis Completed NCT00266734

Search NIH Clinical Center for Inclusion Conjunctivitis

Cochrane evidence based reviews: conjunctivitis, inclusion

Genetic Tests for Inclusion Conjunctivitis

Anatomical Context for Inclusion Conjunctivitis

The Foundational Model of Anatomy Ontology organs/tissues related to Inclusion Conjunctivitis:

19
Conjunctiva Of The Eye

MalaCards organs/tissues related to Inclusion Conjunctivitis:

40
Eye, T Cells

Publications for Inclusion Conjunctivitis

Articles related to Inclusion Conjunctivitis:

(show top 50) (show all 410)
# Title Authors PMID Year
1
Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. 61
33271962 2020
2
Physical distancing and non-respiratory notifiable diseases in the Northern Territory, March-May 2020. 61
33278872 2020
3
Water-filtered Infrared A and visible light (wIRA/VIS) treatment reduces Chlamydia caviae-induced ocular inflammation and infectious load in a Guinea pig model of inclusion conjunctivitis. 61
32653859 2020
4
Chlamydia trachomatis presenting as preseptal cellulitis in a 3-year-old girl. 61
31112775 2019
5
Insertional mutagenesis in the zoonotic pathogen Chlamydia caviae. 61
31697687 2019
6
Symptoms, Signs and Long-term Prognosis of Vertically Transmitted Chlamydia trachomatis Infections. 61
29389825 2018
7
Treatment of Neonatal Chlamydial Conjunctivitis: A Systematic Review and Meta-analysis. 61
30007329 2018
8
Effects of iota-carrageenan on ocular Chlamydia trachomatis infection in vitro and in vivo. 61
30147240 2018
9
Interventions for treating genital Chlamydia trachomatis infection in pregnancy. 61
28937705 2017
10
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. 61
28002109 2017
11
Chlamydial conjunctivitis in newborns: Case report and screening opportunities. 61
28177584 2017
12
Chlamydial eye infections: Current perspectives. 61
28345563 2017
13
[Persistent, therapy-resistant conjunctivitis: consider infection with Chlamydia trachomatis]. 61
28443807 2017
14
Study of the prevalence and association of ocular chlamydial conjunctivitis in women with genital infection by Chlamydia trachomatis, Mycoplasma genitalium and Candida albicans attending outpatient clinic. 61
27588273 2016
15
The presence of Chlamydia phage PhiCPG1 capsid protein VP1 genes and antibodies in patients infected with Chlamydia trachomatis. 61
27213552 2016
16
Chlamydial conjunctivitis: prevalence and serovar distribution of Chlamydia trachomatis in adults. 61
26297635 2015
17
Preventing ophthalmia neonatorum. 61
26236350 2015
18
Conjunctival infection with Chlamydia trachomatis in sexual partners of patients with adult inclusion conjunctivitis. 61
24643518 2015
19
Preventing ophthalmia neonatorum. 61
25838784 2015
20
Chlamydia trachomatis conjunctivitis in a male teenager: a case report. 61
24955802 2014
21
Evaluation of single-dose azithromycin versus standard azithromycin/doxycycline treatment and clinical assessment of regression course in patients with adult inclusion conjunctivitis. 61
24047438 2013
22
Evaluation of direct immunofluorescence assay and cytological examination in comparison to polymerase chain reaction of conjunctival swabs in patients with adult inclusion conjunctivitis. 61
23627371 2013
23
Multiplex PCR testing requires a robust multi-disciplinary strategy to effectively manage identified cases of chlamydial conjunctivitis. 61
23728751 2013
24
[Purulent keratoconjunctivitis due to Neisseria gonorrhoeae and Chlamydia trachomatis coinfection]. 61
23692878 2013
25
[Investigation of Chlamydia trachomatis with Cell Culture, DFA and PCR Methods in the Genital Swab Samples of Symptomatic Patients]. 61
23390905 2013
26
[Prevalence of Chlamydia trachomatis in adults with chronic conjunctivitis in Nisava district]. 61
22650098 2012
27
The use of polymerase chain reaction assay versus cell culture in detecting neonatal chlamydial conjunctivitis. 61
22369307 2012
28
Effect of inflammatory response on in vivo competition between two chlamydial variants in the guinea pig model of inclusion conjunctivitis. 61
22144478 2012
29
Features and serotypes of chlamydial conjunctivitis. 61
22230301 2012
30
Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections. 61
21402767 2011
31
Effect of oral azithromycin in the treatment of chlamydial conjunctivitis. 61
19893589 2010
32
Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency. 61
20502027 2010
33
Bilateral conjunctival MALT lymphoma mimicking chronic conjunctivitis. 61
20523096 2010
34
Chlamydia trachomatis causing neonatal conjunctivitis in a tertiary care center. 61
20061763 2010
35
Recent trends in chlamydial and gonococcal conjunctivitis among neonates and adults in an Irish hospital. 61
18093859 2008
36
Bacterial conjunctivitis: a review for internists. 61
18646586 2008
37
The use of polymerase chain reaction assay versus conventional methods in detecting neonatal chlamydial conjunctivitis. 61
18705621 2008
38
Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. 61
17947266 2007
39
Chlamydial conjunctivitis presenting as pre septal cellulitis. 61
17359543 2007
40
Incidence of neonatal chlamydial conjunctivitis and its association with nasopharyngeal colonisation in a Hong Kong hospital, assessed by polymerase chain reaction. 61
17277388 2007
41
Can chlamydial conjunctivitis result from direct ejaculation into the eye? 61
16942659 2006
42
Otitis media in adults with chlamydial conjunctivitis. 61
16731671 2006
43
Neonatal chlamydial conjunctivitis. 61
16760561 2006
44
Chlamydiales in guinea-pigs and their zoonotic potential. 61
16629952 2006
45
Neonatal haemorrhagic conjunctivitis: a specific sign of chlamydial infection. 61
16495586 2006
46
Chlamydia trachomatis infections in neonates and young children. 61
16210104 2005
47
The Relationship between chlamydia trachomatis and chlamydia pneumoniae as the cause of neonatal conjunctivitis (ophthalmia neonatorum). 61
16088243 2005
48
Conjunctival swab cytology from a guinea pig: it's elementary! 61
15902672 2005
49
Feline chlamydiosis. 61
15948428 2005
50
Cell death, BAX activation, and HMGB1 release during infection with Chlamydia. 61
15488733 2004

Variations for Inclusion Conjunctivitis

Expression for Inclusion Conjunctivitis

Search GEO for disease gene expression data for Inclusion Conjunctivitis.

Pathways for Inclusion Conjunctivitis

GO Terms for Inclusion Conjunctivitis

Biological processes related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to unfolded protein GO:0006986 9.16 TMBIM6 HSPD1
2 response to glucocorticoid GO:0051384 8.96 HSPD1 CPN1
3 B cell activation GO:0042113 8.62 TXLNA HSPD1

Sources for Inclusion Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....